Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX 株式レポート

時価総額：US$5.7b

Amneal Pharmaceuticals 配当と自社株買い

配当金 基準チェック /06

Amneal Pharmaceuticals配当金を支払った記録がありません。

主要情報

0%

配当利回り

0.8%

バイバック利回り

総株主利回り0.8%
将来の配当利回り0%
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向0%

最近の配当と自社株買いの更新

更新なし

Recent updates

Seeking Alpha • 18h

Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism

Summary Amneal Pharmaceuticals has diversified beyond generics, driving margin expansion and improved financial health, but now trades near all-time highs. AMRX’s growth hinges on the Kashiv BioSciences acquisition, which is expected to add biosimilars and support management’s $4.25 billion 2030 revenue target. Despite improved operating leverage and reaffirmed 2026 guidance, persistent debt, settlement costs, and dilution from acquisitions cap free cash flow potential. My DCF analysis suggests AMRX is fully valued for management’s bullish projections; I maintain a neutral/Hold rating given limited upside and execution risks. Read the full article on Seeking Alpha
新しいナラティブ • Jul 17

Biosimilars Expansion And Vertical Integration Will Reshape Long-Term Outlook

Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals focuses on affordable medicines across generics, specialty drugs and biosimilars, with a growing presence in large molecule therapies. What are the underlying business or industry changes driving this perspective?
ナラティブ更新 • Jul 15

AMRX: Biosimilars And 2026 Execution Will Shape Fairly Valued Outlook

Analysts have raised their fair value estimate for Amneal Pharmaceuticals by $1 to $18.25, citing higher price targets from recent research, confidence in growth from Crexont, Women's Health and biosimilars, and support from improving expectations reflected in a modestly higher assumed future P/E multiple. Analyst Commentary Recent Street research on Amneal Pharmaceuticals highlights a mix of enthusiasm around growth drivers like Crexont, Women's Health and biosimilars, alongside a few areas where execution and valuation expectations could face tests.
分析記事 • Jun 21

Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally

Why Amneal Pharmaceuticals Stock Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies. The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies. See our latest analysis for...
ナラティブ更新 • Jun 19

AMRX: Biosimilar Buildout And 2026 Execution Will Shape Fairly Valued Stock

Analysts have nudged their fair value estimate for Amneal Pharmaceuticals up to $17.25 from $17.20, citing higher projected profit margins and renewed confidence in the 2026 outlook as the company works to narrow its valuation gap with peers and advance its biosimilar efforts. Analyst Commentary Recent research on Amneal Pharmaceuticals highlights a mix of optimism on the 2026 setup and some areas where investors may want to stay disciplined on execution and valuation.
ナラティブ更新 • Jun 04

AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound

Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.
ナラティブ更新 • May 04

AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback

Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.
ナラティブ更新 • Apr 19

AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup

Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.
ナラティブ更新 • Apr 02

AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup

Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.
ナラティブ更新 • Mar 18

AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback

Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.
ナラティブ更新 • Mar 04

AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup

Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.
ナラティブ更新 • Feb 17

AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup

Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.
ナラティブ更新 • Feb 03

AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook

Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.
ナラティブ更新 • Jan 19

AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook

Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.
ナラティブ更新 • Jan 05

AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook

Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.
ナラティブ更新 • Dec 13

AMRX: Complex Generics Approvals Will Support Future Earnings Upside

Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.
分析記事 • Nov 30

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...
ナラティブ更新 • Nov 29

AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook

Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.
ナラティブ更新 • Nov 15

AMRX: Sustained Outperformance Will Drive Future Earnings Confidence

Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.
分析記事 • Nov 14

Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...
ナラティブ更新 • Nov 01

AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum

Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.
ナラティブ更新 • Sep 17

Global Health Trends And Pipeline Launches Will Fuel Future Potential

Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.
分析記事 • Aug 08

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a good week for Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shareholders, because the company has just...
分析記事 • Jul 24

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S

With a price-to-sales (or "P/S") ratio of 0.9x Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) may be sending very bullish...
User avatar
新しいナラティブ • Mar 22

CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market

The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.
Seeking Alpha • Mar 19

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Summary Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. Key growth areas include biosimilars, specialty drugs like CREXONT, and the high-growth GLP-1 weight loss market, positioning AMRX stock for long-term success. Read the full article on Seeking Alpha

決済の安定と成長

配当データの取得

安定した配当: AMRXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: AMRXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Amneal Pharmaceuticals 配当利回り対市場
AMRX 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (AMRX)0%
市場下位25% (US)1.3%
市場トップ25% (US)4.1%
業界平均 (Pharmaceuticals)2.0%
アナリスト予想 (AMRX) (最長3年)0%

注目すべき配当: AMRXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: AMRXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: AMRX US市場において目立った配当金を支払っていません。

株主配当金

キャッシュフローカバレッジ: AMRXが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/20 06:32
終値2026/07/20 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Amneal Pharmaceuticals, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20

アナリスト機関
Glen SantangeloBarclays
Gary NachmanBMO Capital Markets Equity Research
David BuckB. Riley Securities, Inc.